Efficacy and Safety of Rivaroxaban vs. Warfarin in Patie Fibrillation and a History of Cancer: Observations From

European Heart Journal Quality of Care & Clinical Outcomes

5, 145-152

DOI: 10.1093/ehjqcco/qcy040

Citation Report

#	Article	IF	Citations
1	Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 8, e012540.	5.8	56
2	Direct Oral Anticoagulants in Patients With Cancer. American Journal of Health-System Pharmacy, 2019, 76, 1019-1027.	1.4	4
3	Anticoagulation of Cancer Patients With Non-Valvular Atrial Fibrillation Receiving Chemotherapy: Guidance From the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1247-1252.	5.0	78
4	Considerations for Long-Term Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and Cancer. Journal of Oncology Practice, 2019, 15, 651-652.	2.4	0
5	Efficacy and Safety of Oral Anticoagulants in Atrial Fibrillation Patients With Cancer—A Network Meta-Analysis. Heart Failure Reviews, 2020, 25, 823-831.	6.2	20
6	Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 314-321.	4.6	41
7	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. Journal of the American Heart Association, 2020, 9, e017316.	5.8	50
8	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Current Heart Failure Reports, 2020, 17, 365-383.	4.5	21
9	Direct Oral Xa Inhibitors Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Meta-Analysis. Journal of Cardiovascular Medicine, 2020, 21, 570.	2.3	9
10	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	3.8	582
11	The Association of New-Onset Atrial Fibrillation and Risk of Cancer: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2020, 2020, 2372067.	1.5	17
12	Complex Clinical Scenarios With the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Multidisciplinary Expert Advisory Board. Netherlands Heart Journal, 2020, 28, 504-513.	2.6	2
13	Direct Versus Conventional Anticoagulants for Treatment of Cancer Associated Thrombosis: A Pooled and Interaction Analysis Between Observational Studies and Randomized Clinical Trials. Annals of Translational Medicine, 2020, 8, 95.	2.5	10
14	Cancer-Specific Ischemic Complications in Elderly Patients With Atrial Fibrillation: Data From the Prospective ATHERO-AF Study. International Journal of Cancer, 2020, 147, 3424-3430.	5.0	16
15	Factors for Recurrent Stroke Among Asian Patients With Non-Valvular Atrial Fibrillation Under Non-Vitamin K Antagonist Oral Anticoagulant Therapy. Journal of the Formosan Medical Association, 2020, 119, 1799-1806.	2.2	11
16	Oral Anticoagulant Treatment in Patients With Atrial Fibrillation and Cancer. Thrombosis and Haemostasis, 2020, 120, 194-196.	4.6	0
17	Safety of Catheter Ablation of Atrial Fibrillation in Cancer Survivors. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 419-426.	2.7	24
18	Direct Oral Anticoagulants in the Prevention of Stroke in Breast Cancer Patients With Atrial Fibrillation During Adjuvant Endocrine Therapy: A Cohort Study. International Journal of Cardiology, 2021, 324, 78-83.	3.2	13

#	Article	IF	Citations
19	Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation and Cancer a Meta-Analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 419-429.	2.2	51
20	Direct Oral Anticoagulation in Cancer Patients. , 2021, .		0
21	Safety and Efficacy of New Oral Anticoagulants Compared to Those of Warfarin in AF Patients With Cancer: A Meta-Analysis of Randomized Clinical Trials and Observational Studies. European Journal of Clinical Pharmacology, 2021, 77, 849-857.	3.8	13
22	Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks. TH Open, 2021, 05, e176-e182.	1.8	13
23	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	8.4	1,074
24	Cancer and Atrial Fibrillation: Epidemiology, Mechanisms, and Anticoagulation Treatment. Progress in Cardiovascular Diseases, 2021, 66, 28-36.	9.7	44
25	Cardiovascular Oncology: The Need for a Multidisciplinary Approach. Seminars in Thrombosis and Hemostasis, 2021, 47, 907-913.	4.1	3
26	Bleeding Complications in Patients With Gastrointestinal Cancer and Atrial Fibrillation Treated With Oral Anticoagulants. Cancer Medicine, 2021, 10, 4405-4414.	3.8	13
27	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke, 2021, 52, e364-e467.	9.1	3,042
28	ANMCO Position Paper: Cardio-Oncology in the COVID Era (CO and CO).. European Heart Journal Supplements, 2021, 23, C128-C153.	2.9	7
29	Risk of Major Bleeding Associated With Concomitant Use of Anticancer Drugs and Direct Oral Anticoagulant in Patients With Cancer and Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2022, 53, 633-645.	2.2	17
30	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer. JACC: CardioOncology, 2021, 3, 411-424.	6.8	52
31	Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants. Stroke, 2021, 52, 3132-3141.	9.1	35
32	Anticoagulation in Patients With Atrial Fibrillation and Active Cancer: An International Survey on Patient Management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	6.1	52
33	Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Cancer Patients With Atrial Fibrillation. Anatolian Journal of Cardiology, 2020, 23, 10-18.	1.3	11
34	Utilidad de los anticoagulantes de acción directa en los pacientes con cáncer. REC: CardioClinics, 2019, 54, 145-147.	0.3	0
35	Problematika Antikoagulace z Pohledu Nefrologa. Intervencni A Akutni Kardiologie, 2019, 18, 134-136.	0.0	0
36	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. Side Effects of Drugs Annual, 2020, 42, 337-360.	0.0	1

#	Article	IF	Citations
37	Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 766377.	3.2	17
38	Incidence and Predictors of Bleeding in Patients With Cancer and Atrial Fibrillation. American Journal of Cardiology, 2022, 167, 139-146.	2.4	23
39	Anticoagulation for Atrial Fibrillation in Patients With Cancer. Circulation Journal, 2022, 86, 211-212.	4.0	3
40	Hematuria in Anticoagulated Patients With Atrial Fibrillation and Urologic Cancer. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12629.	3.3	3
41	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: A Position Paper From the ESC Working Group on Thrombosis, in Collaboration With the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	8.4	62
42	Anticoagulation for Atrial Fibrillation in Active Cancer (Review). Oncology Letters, 2022, 23, 1-10.	2.4	19
43	Impact of Malignancy on Outcomes in European Patients With Atrial Fibrillation: A Report From the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation General Long-Term Registry. European Journal of Clinical Investigation, 2022, 52, e13773.	4.4	11
44	Use of Oral Anticoagulants Among Individuals With Cancer and Atrial Fibrillation in the United States, 2010–2016. Pharmacotherapy, 2022, 42, 375-386.	4.3	15
45	Factor Xa Inhibitor for Venous Thromboembolism Management in Patient With Cancer: A Systematic Review and Meta-Analysis. F1000Research, 2021, 10, 1257.	1.1	1
46	Prognostic Impact of a History of Cancer and Atrial Fibrillation in Antithrombotic Therapy for Chronic Heart Failure. ESC Heart Failure, 2022, 9, 2445-2454.	4.1	8
47	Cancer Patients With Acute Coronary Syndrome Have Non-Superior Bleeding Risk Compared to Patients With Similar Characteristics – A Propensity Score Analysis From the ProACS Registry. Revista Portuguesa De Cardiologia, 2022, 41, 573-582.	1.1	6
48	Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions From the Italian National Pharmacovigilance Network. Journal of Clinical Medicine, 2022, 11, 3207.	3.8	7
49	Stroke Risk Assessment and Atrial Fibrillation (AF) in Cancer Patients. , 2022, .		0
50	Oral Anticoagulants in Patients With Atrial Fibrillation and Active Cancer. Reviews in Cardiovascular Medicine, 2022, 23, 242.	2.5	1
51	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thrombosis and Haemostasis, 2022, 122, 1625-1652.	4.6	110
52	Treatment Options in AF Patients With Cancer; Focus on Catheter Ablation. Journal of Clinical Medicine, 2022, 11, 4452.	3.8	8
53	Atrial Fibrillation and Cancer Patients: Mechanisms and Management. Current Cardiology Reports, 2022, 24, 1517-1527.	4.5	31
54	Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-Analysis. Current Problems in Cardiology, 2022, 47, 101346.	4.1	11

#	Article	IF	Citations
55	2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration With the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-Oncology of the European Society of Cardiology (ESC). European Heart Journal Cardiovascular Imaging, 2022, 23, e333-e465.	4.7	381
56	2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration With the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-Oncology of the European Society of Cardiology (ESC). European Heart Journal, 2022, 43, 4229-4361.	14.7	3,166
57	Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer. JACC: CardioOncology, 2022, 4, 341-350.	6.8	12
58	Superiority of Direct Oral Anticoagulants Over Vitamin K Antagonists in Oncological Patients With Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes. Journal of Clinical Medicine, 2022, 11, 5712.	3.8	10
59	Bleeding and Thrombotic Events in Atrial Fibrillation Patients With Cancer: A Systematic Review and Meta-Analysis. Internal and Emergency Medicine, 2023, 18, 655-665.	4.8	16
60	Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database. Journal of the American Heart Association, 2022, 11, e026388.	5.8	21
61	Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e008951.	5.6	14
62	Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials. Biomedicines, 2023, 11, 131.	4.9	12
63	Current Perspectives on the Clinical Management of Cryptogenic Stroke. Expert Review of Neurotherapeutics, 2023, 23, 213-226.	4.5	18
64	Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients. Cancers, 2023, 15, 2574.	5.3	12
65	Safety of Catheter Ablation for Atrial Fibrillation in Patients With Cancer: A Nationwide Cohort Study. Postgraduate Medicine, 2023, 135, 562-568.	3.0	11
66	Risk of Arterial Thromboembolism, Bleeding and Mortality in Atrial Fibrillation Patients With Comorbid Cancer: A Systematic Review and Meta-Analysis. Hellenic Journal of Cardiology, 2023, 74, 65-73.	2.0	10
67	Evaluating Efficacy and Safety of Oral Anticoagulation in Adult Patients With Atrial Fibrillation and Cancer: A Systemic Review and Meta-Analysis. Thrombosis Update, 2023, 12, 100144.	1.6	4
68	Management of Patients Treated With Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. Journal of Clinical Medicine, 2023, 12, 5955.	3.8	54
69	Outcome of Cancer Patients After Atrial Fibrillation Ablation: Insights From the China-AF Registry. PACE - Pacing and Clinical Electrophysiology, 2023, 46, 1419-1429.	1.3	7
70	Common Cancer Types and Risk of Stroke and Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Study in England. Journal of the American Heart Association, 2023, 12, e029423.	5.8	23
71	Relationships, Current Issues, Safety and Efficacy of Oral Anticoagulation in Cancer Patients With Atrial Fibrillation. Journal of Clinical Medicine, 2023, 12, 6559.	3.8	0
72	Current Data and Future Perspectives on Patients With Atrial Fibrillation and Cancer. Cancers, 2023, 15, 5357.	5.3	1

#	Article	IF	Citations
73	Mechanisms, Prevalence and Management of Cardiac Arrhythmias in Cancer Patients: A Comprehensive Review. Future Cardiology, 2023, 19, 707-718.	1.2	2
74	Clinical Outcomes and Mortality in Patients With Atrial Fibrillation and Recently Diagnosed Lung Cancer in Oncology Outpatient Settings. Current Problems in Cardiology, 2024, 49, 102239.	4.1	4
75	Antithrombotic Strategy in Cancer Patients Comorbid With Acute Coronary Syndrome and Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2023, 10, 1325488.	3.2	5
76	When Anticoagulation Management in Atrial Fibrillation Becomes Difficult: Focus on Chronic Kidney Disease, Coagulation Disorders, and Cancer. Blood Reviews, 2024, 65, 101171.	7.6	9
77	Malignancy-Associated Ischemic Stroke: Implications for Diagnostic and Therapeutic Workup. CNS Neuroscience and Therapeutics, 2024, 30, e14619.	6.5	5
78	Arrhythmias and Conduction Disorders in HSCT. , 2024, .		0
79	Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry. JACC: Advances, 2024, 3, 100991.	3.2	7
80	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Cancer: A Target Trial Emulation From SEER-Medicare Database. Cardiovascular Drugs and Therapy, 2025, 39, 1-13.	4.1	9
81	Comparison of the Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients With or Susceptible to Thromboembolic Events. Iranian South Medical Journal, 2023, 26, 51-62.	0.3	0
82	Use of DOACs in Frail Elderly Patients in Light of Class Genericization. International Journal of Cardiology, 2024, 411, 132276.	3.2	2
83	Arterial Thrombosis in Patients With Cancer. Cancers, 2024, 16, 2238.	5.3	13
84	Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer. European Heart Journal Open, 2024, 4, oeae053.	3.6	13
85	Antithrombotic Therapy in Cancer Patients With Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.). Hamostaseologie, 2026, 46, 250-271.	1.5	2
86	Crosslink Between Atrial Fibrillation and Cancer: A Therapeutic Conundrum. Cardio-Oncology, 2024, 10, 1-15.	5.3	7
87	2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), With the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal, 2024, 45, 3314-3414.	14.7	3,324
88	Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC: CardioOncology, 2024, 6, 631-654.	6.8	93
89	Arrhythmia Challenges in Cardio-Oncology: High-Risk Therapies, Management, and Anticoagulation. Cardiology Clinics, 2025, 43, 43-56.	1.4	3
90	Long-Term Risks and Benefits of Oral Anticoagulation in Atrial Fibrillation Patients With Cancer: A Report From the GLORIA-AF Registry. European Journal of Clinical Investigation, 2025, 55, e14347.	4.4	9

#	Article	IF	Citations
91	Atrial Fibrillation in Patients With Breast Cancer: A Literature Review. Cardiology and Therapy, 2025, 14, 1-15.	3.6	2
92	Major Bleeding and Thromboembolism Risks of Antithrombotic Treatment in Patients With Incident Atrial Fibrillation/Flutter and a History of Cancer. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102679.	3.3	1
93	Major Bleeding and Thromboembolic Complications Associated With Antithrombotic Treatment in Patients With Atrial Fibrillation/Flutter and Incident Cancer. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102697.	3.3	1
94	Atrial Fibrillation in Cancer Patients: Epidemiology, Identification and Management. Seminars in Cancer Biology, 2025, 111, 39-47.	19.9	8
95	CAVTEMeta. Advances in Clinical Medicine, 2025, 15, 1887.	0.1	0
96	Diagnosis and Management of Atrial Arrhythmias in Cancer Patients. Current Cardiology Reports, 2025, 27, 103.	4.5	4
97	Comparative Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Cancer Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Emergency Medicine, 2025, 0, 288-304.	1.5	2
98	Arrhythmias, Conduction Disorders and Sudden Cardiac Death in Cancer Patients and Survivors: Expert Opinion of the Working Groups on Cardio-Oncology and on Electrophysiology of the Hellenic Cardiac Society. Cardio-Oncology, 2025, 11, 71.	5.3	7
99	Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. JAMA Cardiology, 2025, 10, 1305-1314.	16.3	5
100	Comparing Survival With Vitamin K Antagonists, Low-Molecular-Weight Heparin, and Direct Oral Anticoagulants in Patients With Cancer-a Systematic Review and Meta-Analysis. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 103268.	3.3	0
101	Stroke Predictors for Atrial Fibrillation – Outside the CHA2DS2-VA. Internal Medicine Journal, 2026, 56, 533-543.	1.6	0
102	Risks of Thrombosis and Hemorrhage in Concurrent Use of Anticoagulants and Potential Interacting Prostate Cancer Agents. Cancer, 2026, 132, e70266.	5.1	2
103	Utilisation des bases de l'Assurance Maladie pour l'analyse de l'utilisation et de la sécurité des anticoagulants oraux dans la fibrillation auriculaire. , 0, .		0
104	Practical Considerations in the Management of Patients With Atrial Fibrillation/Flutter and Hematologic Malignancies. Journal of Oncology Pharmacy Practice, 2026, .	1.5	0
105	Atrial Fibrillation Post Hematopoietic Stem Cell Transplant: Incidence, Risk Factors, and Management Challenges. Frontiers in Cardiovascular Medicine, 2026, 13, 1781484.	3.2	1
106	New Insights Into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban. Journal of Clinical Pharmacology, 2026, 66, e70236.	2.4	0
107	Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation Patients With Cancer by Anticoagulation Quality. Cancer, 2026, 132, e70501.	5.1	0
108	Anticoagulation Strategies and Pulmonary Safety in Patients With Active Lung Cancer and Atrial Fibrillation: A Large-Scale, Competing Risk Analysis of 2000 Patients. Heart and Lung: Journal of Acute and Critical Care, 2026, 80, 102898.	2.8	0

#	Article	IF	Citations
109	Real-World Safety and Clinical Outcomes of Apixaban in Patients With Cancer and Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2026, 13, 1893856.	3.2	0
110	Prevalence, Incidence, and Impact of Cancer in Atrial Fibrillation: A Systematic Review and Meta-Analysis of 70,000,000 Patients. Health Science Reports, 2026, 9, e73099.	3.1	0